NCT04624308View on ClinicalTrials.gov

Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

October 30, 2025

Study Completion Date

December 30, 2025

Conditions
Hypopharyngeal Neoplasm Malignant Primary
Interventions
DRUG

Toripalimab

Toripalimab 240mg d1，Q3W. Given with TPF during inductive chemotherapy and definitive radiotherapy.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors
collaborator

Shanghai Junshi Bioscience Co., Ltd.

OTHER

lead

Sun Yan

OTHER